Livasupril (micronized fenofibrate/pitavastatin) / Hanlim Pharma - LARVOL DELTA

An Observational Study on the Identification of Prescription Patterns of STAFEN Cap (clinicaltrials.gov) - P=N/A | N=4000 | Recruiting | Sponsor: Hanlim Pharm. Co., Ltd.

New trial • Dyslipidemia • Metabolic Disorders

Efficacy and Tolerability of Pitavastatin Versus Pitavastatin/Fenofibrate in High-risk Korean Patients with Mixed Dyslipidemia: A Multicenter, Randomized, Double-blinded, Parallel, Therapeutic Confirmatory Clinical Trial. (PubMed, Clin Ther) - P3 | "In these Korean patients with mixed dyslipidemia and a high risk for CVD, combination therapy with pitavastatin/fenofibrate was associated with a greater reduction in non-HDL-C compared with that with pitavastatin monotherapy, and a significantly improvement in other lipid levels. Moreover, the combination therapy was well tolerated, with a safety profile similar to that of statin monotherapy. Therefore, pitavastatin/fenofibrate combination therapy could be effective and well tolerated in patients with mixed dyslipidemia. ClinicalTrials.gov identifier: NCT03618797."

Clinical • Journal • Cardiovascular • Coronary Artery Disease • Dyslipidemia • Heart Failure • Metabolic Disorders • Myocardial Infarction • APOB • CRP